Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

Study summary

Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment. It, however, remains unclear if these new diagnostic technologies truly influence clinical and economic outcomes. This study will evaluate if patients treated according to the results of the NantHealth GPS Cancer test achieve optimal outcomes compared to patients whose treatment are discordant with GPS Cancer recommendations.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNantHealth GPS Cancer Test

The study team can explain what participation involves.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 20, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?Cota Inc.

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Cota Inc.
Interventions being studied: Diagnostic Test: NantHealth GPS Cancer Test

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Metastatic or stage IV→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Pancreatic cancer patients ineligible for curative surgery at time of entry will be eligible for enrollment.
Metastatic breast cancer at any time in their treatment history will be eligible for enrollment.
Advanced stage (non-resectable/metastatic/incurable) lung cancer patients will be eligible for enrollment.
Metastatic colon cancer patients not amenable to curative therapy will be eligible for enrollment.
Metastatic non-resectable malignant melanoma patients will be eligible for enrollment. NantHealth GPS Cancer in Advanced Cancers
Metastatic hormone refractory prostate cancer patients will be eligible for enrollment. Patients must have tumor tissue available prior to the initiation of the current line of treatment available for GPS Cancer testing.
Metastatic bladder cancer
Non-resectable metastatic Renal carcinoma
Non-resectable metastatic Head and Neck cancer
Metastatic Ovarian cancer
Metastatic Cervical cancer
Metastatic Sarcoma
Patients must sign informed consent for this study.
Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs.

Reasons someone may not be able to joinExclusion criteria

Pregnancy.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

RCCA - Central Jersey DivisionEast Brunswick, New Jersey
RCCA - Freehold DivisionFreehold, New Jersey
Hackensack Meridian Health SystemHackensack, New Jersey
RCCA - Hackettstown DivisionHackettstown, New Jersey
RCCA - Howell DivisionHowell Township, New Jersey
RCCA - Little Silver DivisionLittle Silver, New Jersey
RCCA - Marmora DivisionMarmora, New Jersey
RCCA - Mount Holly DivisionMount Holly, New Jersey
RCCA - Pompton Plains DivisionPompton Plains, New Jersey
RCCA - Sparta DivisionSparta, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 20, 2018. Always confirm current availability with the study team.

View original record ↗